A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response to Previous TNF Therapy (Cohort 2)

Trial Profile

A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response to Previous TNF Therapy (Cohort 2)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs GDC 0853 (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 22 Sep 2017 Planned number of patients changed from 580 to 600.
    • 22 Sep 2017 Planned End Date changed from 31 Jul 2018 to 26 Jun 2018.
    • 22 Sep 2017 Planned primary completion date changed from 31 Jul 2018 to 26 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top